Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122573 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11TSHRENPEPSLC7A5 | |
| Hydrochloric Acid SCHEMBL9589944 | 0.98 | PTGS1 (0.44) | PTGS1SLC7A11TSHRENPEPSLC7A5 | |
| Hydrochloric Acid SCHEMBL8596085 | 0.98 | PTGS1 (0.44) | PTGS1SLC7A11TSHRENPEPSLC7A5 | |
| SCHEMBL24359844 | 0.81 | PTGS1 (0.41) | PTGS1SLC7A11ENPEPSLC7A5 | |
| SCHEMBL23408842 | 0.81 | SLC7A5 (0.43) | PTGS1SLC7A11ENPEPSLC7A5ANPEP | |
| SCHEMBL6535208 | 0.80 | PTGS1 (0.44) | PTGS1SLC7A11ENPEPSLC7A5ANPEP | |
| SCHEMBL5330308 | 0.79 | TSHR (0.40) | TSHRSLC7A5LMNAHCAR2CA12 | |
| SCHEMBL9384783 | 0.79 | PTGS1 (0.48) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL30606392 | 0.79 | TSHR (0.40) | TSHRSLC7A5LMNAHCAR2CA12 | |
| SCHEMBL13155620 | 0.79 | TSHR (0.40) | TSHRSLC7A5LMNAHCAR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2022084747-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| US-9629857-B2 | Therapeutic uses of glutathione mimics | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2017-04-25 | — | — | US | disclosed |
| US-9579331-B2 | Therapeutic uses of glutathione mimics | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150224123-A1 | THERAPEUTIC USES OF GLUTATHIONE MIMICS | NORTHERN ILLINOIS RESEARCH FOUNDATION | 2015-08-13 | — | — | US | disclosed |
| US-20150224122-A1 | THERAPEUTIC USES OF GLUTATHIONE MIMICS | NORTHERN ILLINOIS RESEARCH FOUNDATION | 2015-08-13 | — | — | US | disclosed |
| US-9084803-B2 | Therapeutic uses of glutathione mimics | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20090005349-A1 | THERAPEUTIC USES OF GLUTATHIONE MIMICS | NORTHERN ILLINOIS RESEARCH FOUNDATION | 2009-01-01 | — | — | US | disclosed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | disclosed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-1998055135-A1 | PROTECTIVE COMPOSITIONS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1998-12-10 | — | — | WO | disclosed |
| EP-0546063-A1 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND USES | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992004024-A2 | TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND METHOD | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224122-A1 | THERAPEUTIC USES OF GLUTATHIONE MIMICS | GSTP1, GSTA1, GSTM1 | PTGS1 166/4885SLC7A11 41/4885TSHR 2449/4885 |
| US-20150224123-A1 | THERAPEUTIC USES OF GLUTATHIONE MIMICS | GSTP1, GSTA1, GSTM1 | PTGS1 166/4885SLC7A11 41/4885TSHR 2449/4885 |
| US-20090005349-A1 | THERAPEUTIC USES OF GLUTATHIONE MIMICS | GSTP1, GSTA1, GSTM1 | PTGS1 166/4885SLC7A11 41/4885TSHR 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.